Literature DB >> 27707913

Need for Outcome Scenario Analysis of Clinical Trials in Diabetes.

Rosa Garcia-Verdugo1, Michael Erbach1, Oliver Schnell1,2.   

Abstract

Since the FDA requirement for cardiovascular safety of all new antihyperglycemic drugs to enter the market, the number and extent of phase 3 clinical trials has markedly increased. Unexpected trial results imply an enormous economic, personal and time cost and has deleterious effects over R&D. To prevent unforeseen developments in clinical trials, we recommend performing a comprehensive prospective outcome scenario analysis before launching the trial. In this commentary, we discuss the most important factors to take in consideration for prediction of clinical trial outcome scenarios and propose a theoretical model for decision making.

Entities:  

Keywords:  clinical trials; outcome prediction; scenario analysis

Mesh:

Substances:

Year:  2016        PMID: 27707913      PMCID: PMC5478029          DOI: 10.1177/1932296816670925

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  17 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  Hamsi scoring in the prediction of unfavorable outcomes from tuberculous meningitis: results of Haydarpasa-II study.

Authors:  Hakan Erdem; Derya Ozturk-Engin; Hulya Tireli; Gamze Kilicoglu; Sylviane Defres; Serda Gulsun; Gonul Sengoz; Alexandru Crisan; Isik Somuncu Johansen; Asuman Inan; Mihai Nechifor; Akram Al-Mahdawi; Rok Civljak; Muge Ozguler; Branislava Savic; Nurgul Ceran; Bruno Cacopardo; Ayse Seza Inal; Mustafa Namiduru; Saim Dayan; Uner Kayabas; Emine Parlak; Ahmad Khalifa; Ebru Kursun; Oguz Resat Sipahi; Mucahit Yemisen; Ayhan Akbulut; Mehmet Bitirgen; Natasa Popovic; Bahar Kandemir; Catalina Luca; Mehmet Parlak; Jean Paul Stahl; Filiz Pehlivanoglu; Soline Simeon; Aysegul Ulu-Kilic; Kadriye Yasar; Gulden Yilmaz; Emel Yilmaz; Bojana Beovic; Melanie Catroux; Botond Lakatos; Mustafa Sunbul; Oral Oncul; Selma Alabay; Elif Sahin-Horasan; Sukran Kose; Ghaydaa Shehata; Katell Andre; Gorana Dragovac; Hanefi Cem Gul; Ahmet Karakas; Stéphane Chadapaud; Yves Hansmann; Arjan Harxhi; Valerija Kirova; Isabelle Masse-Chabredier; Serkan Oncu; Alper Sener; Recep Tekin; Nazif Elaldi; Ozcan Deveci; Hacer Deniz Ozkaya; Oguz Karabay; Seniha Senbayrak; Canan Agalar; Haluk Vahaboglu
Journal:  J Neurol       Date:  2015-01-30       Impact factor: 4.849

3.  Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.

Authors:  J Dziuba; P Alperin; J Racketa; U Iloeje; D Goswami; E Hardy; I Perlstein; H L Grossman; M Cohen
Journal:  Diabetes Obes Metab       Date:  2014-02-19       Impact factor: 6.577

4.  Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Anthony H Barnett; Ambrish Mithal; Jenny Manassie; Russell Jones; Henning Rattunde; Hans J Woerle; Uli C Broedl
Journal:  Lancet Diabetes Endocrinol       Date:  2014-01-24       Impact factor: 32.069

5.  Cross-trial prediction of treatment outcome in depression: a machine learning approach.

Authors:  Adam Mourad Chekroud; Ryan Joseph Zotti; Zarrar Shehzad; Ralitza Gueorguieva; Marcia K Johnson; Madhukar H Trivedi; Tyrone D Cannon; John Harrison Krystal; Philip Robert Corlett
Journal:  Lancet Psychiatry       Date:  2016-01-21       Impact factor: 27.083

6.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

7.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Authors:  Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder
Journal:  N Engl J Med       Date:  2016-02-17       Impact factor: 91.245

8.  Application of critical path analysis in clinical trials.

Authors:  Amal Kumar; Bhaswat S Chakraborty
Journal:  J Adv Pharm Technol Res       Date:  2016 Jan-Mar

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Authors:  David Fitchett; Bernard Zinman; Christoph Wanner; John M Lachin; Stefan Hantel; Afshin Salsali; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  Eur Heart J       Date:  2016-01-26       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.